NTQ3617

Dose escalation: (1) Evaluate the safety and tolerability of NTQ3617 tablets in patients with advanced malignant solid tumors; (2) Evaluate the dose-limiting toxicity (DLT) of NTQ3617 tablets and determine the maximum tolerated dose (MTD). Dose expansion: (1) Evaluate the RP2D of NTQ3617 tablets in patients with advanced malignant solid tumors with MTAP deletion; (2) Further evaluate the safety and tolerability of NTQ3617 tablets. Secondary objectives: · To evaluate the pharmacokinetic (PK) characteristics of NTQ3617 tablets in patients with advanced malignant solid tumors; · To evaluate the changes in plasma S-adenosylmethionine (SAM) concentrations and determine the pharmacodynamic (PD) characteristics of NTQ3617; · To evaluate the preliminary efficacy (ORR, DCR, DOR, PFS, etc.) of NTQ3617 tablets in the treatment of advanced malignant solid tumors and MTAP-deficient tumor populations; · If data permit, all data on NTQ3617 blood drug concentrations will be used for population pharmacokinetic (PopPK) analysis to characterize the PK characteristics of NTQ3617 in patients with indications and to evaluate the relationship between NTQ3617 exposure in humans and PD, efficacy, and adverse events. Exploratory objectives: · To conduct an exploratory analysis of changes in symmetric dimethylarginine (SDMA) in tumor tissues before and after administration; · To explore potential other biomarkers through biochemical or genetic analysis of tumor samples.